Forma Therapeutics is a clinical-stage biopharmaceutical company focused on transforming the lives of patients with sickle cell disease (SCD) and rare blood disorders. Etavopivat, Forma Therapeutics’ lead development candidate, is an investigational oral, once-daily, selective pyruvate kinase-R (PKR) activator being developed to improve anemia and red blood cell health in people with SCD, a seriously debilitating, life-threatening and life shortening disease.
Novo Nordisk acquired all outstanding shares of common stock of Forma at a price of $20 per share in cash. At the completion of the merger, Forma became a wholly owned subsidiary of Novo Nordisk. The common stock of Forma will no longer be listed or traded on the Nasdaq Global Select Market.
The Goodwin team consisted of Stuart Cable, Lisa Haddad, Andrew Goodman, Lillian Kim, Tevia Pollard, Cynthia (Xiaoyue) Li, Patrick O’Brien, Stephanie Barbanell and Adanna Uwazurike (Public M&A); William Collins, Gabriela Morales-Rivera, Kathryn Clerici and Kimberly Rodriguez (Corporate); Monica Patel, Adrean Taylor and Chris Jones (ERISA & Executive Compensation); Jennifer Fay and Tom McCarthy (Employment); Janet Andolina and Matthew Tippett (Tax); Caroline Bullerjahn and Viktors Dindzans (Litigation); Arman Oruc, Charlie Stewart and Simone Waterbury (Antitrust); Roger Cohen and Heath Ingram (Healthcare); Susan Lee and Joe Thomas (FDA); Catherine McCarty (Intellectual Property); Chris Denn (Licensing); Jacqueline Klosek and Paul Thompson (Privacy); and Richard Matheny and Axel Urie (Global Trade).
For more details, read the press release.